AVPR2 and autosomal dominant polycystic kidney disease: A vasopressin V2 receptor (V2R) antagonist, tolvaptan, was recently approved to preserve kidney function in ADPKD by lowering vasopressin-mediated cAMP increase (Chebib and Torres 2021).